0RC7 Stock Overview A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Hansa Biopharma AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Hansa Biopharma Historical stock prices Current Share Price SEK 34.93 52 Week High SEK 57.30 52 Week Low SEK 26.24 Beta 1.49 1 Month Change 15.66% 3 Month Change -14.39% 1 Year Change -2.20% 3 Year Change -59.49% 5 Year Change -50.35% Change since IPO -15.40%
Recent News & Updates
Hansa Biopharma Announces Positive Full Results from 15-HMedIdeS-09 Phase 2 Study and comparative Analysis of Imlifidase in Patients with Guillain-Barre Syndrome Dec 19
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of Imlifidase in Anti-Glomerular Basement Membrane Disease Dec 06
Genethon and Hansa Biopharma Announce Initiation of A Phase 2 Trial of Imlifidase as A Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome Dec 03
Hansa Biopharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025 Nov 20
Third quarter 2024 earnings released: kr1.53 loss per share (vs kr4.78 loss in 3Q 2023) Oct 18
Hansa Biopharma's Hnsa-5487 Achieves Rapid and Highly Robust Igg Reduction by More Than 95% and Clear Redosing Potential in First-In-Human Trial Oct 07 See more updates
Hansa Biopharma Announces Positive Full Results from 15-HMedIdeS-09 Phase 2 Study and comparative Analysis of Imlifidase in Patients with Guillain-Barre Syndrome Dec 19
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of Imlifidase in Anti-Glomerular Basement Membrane Disease Dec 06
Genethon and Hansa Biopharma Announce Initiation of A Phase 2 Trial of Imlifidase as A Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome Dec 03
Hansa Biopharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025 Nov 20
Third quarter 2024 earnings released: kr1.53 loss per share (vs kr4.78 loss in 3Q 2023) Oct 18
Hansa Biopharma's Hnsa-5487 Achieves Rapid and Highly Robust Igg Reduction by More Than 95% and Clear Redosing Potential in First-In-Human Trial Oct 07 Hansa Biopharma AB (publ) to Report Nine Months, 2025 Results on Oct 23, 2025
Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September Aug 23
Second quarter 2024 earnings released: kr3.30 loss per share (vs kr4.79 loss in 2Q 2023) Jul 19 Hansa Biopharma AB (publ) to Report Q1, 2025 Results on Apr 17, 2025
Hansa Biopharma AB (publ) Announces Board Appointments Jun 28
Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial May 31
New minor risk - Shareholder dilution Apr 14 Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million. Apr 12
Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022) Mar 23
Hansa Biopharma AB (Publ) Announces CFO Changes Feb 22
No longer forecast to breakeven Feb 05
Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022) Feb 02 Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024
Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024 Jan 19
Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 Jan 07
Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 Jan 06
Forecast to breakeven in 2026 Dec 31
Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation Dec 15
Hansa Biopharma Nomination Committee Formed Dec 14
President & CEO recently bought kr115k worth of stock Dec 11
Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial Dec 07 Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024 Nov 29
Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024 Nov 27
Third quarter 2023 earnings released: kr4.78 loss per share (vs kr3.45 loss in 3Q 2022) Oct 31
New minor risk - Profitability Oct 30
Hansa Biopharma Announces Results from an Extended Pooled Analysis Using Data from the 17-Hmedides-14 Study, an International Long-Term Follow-Up Study of Patients Who Have Received A Kidney Transplant Following Desensitization with Imlifidase, Showing Sustained Positive Outcomes Out to 5 Years in the Majority of Highly Sensitized Patients Who Received an Imlifidase-Enabled Kidney Transplant Oct 17
New minor risk - Profitability Oct 13 Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients
Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487 Oct 10
Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023 Sep 03
Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma Sep 02 Hansa Biopharma AB (publ) to Report Q1, 2024 Results on Apr 17, 2024
Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis Jul 21
Second quarter 2023 earnings released: kr4.79 loss per share (vs kr3.82 loss in 2Q 2022) Jul 20
Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation Jul 12
New minor risk - Share price stability Jun 09
Hansa Biopharma Announces First Patient Dosed with Imlifidase in a Global Pivotal Phase 3 Trial in Anti-Inaugular Basement Membrane (anti-GBM) Disease May 30
First quarter 2023 earnings released: kr3.92 loss per share (vs kr3.11 loss in 1Q 2022) Apr 20
Full year 2022 earnings released: kr13.57 loss per share (vs kr12.33 loss in FY 2021) Feb 06
Hansa Biopharma Announces Planned Departure of Chief Scientific Officer Christian Kjellman Jan 31
Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic Jan 03
Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic Jan 02
Hansa Biopharma AB (publ) Announces Formation of Nomination Committee Dec 23 Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering. Dec 14
Hansa Biopharma AB (Publ) Announces Positive Reimbursement Decision in Italy for Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation Dec 08
Hansa Biopharma AB Announces Positive Topline Data from the Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation Nov 29 Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023 Nov 03
Third quarter 2022 earnings released: kr3.45 loss per share (vs kr3.34 loss in 3Q 2021) Oct 21 Hansa Biopharma AB (publ) to Report First Half, 2023 Results on Jul 20, 2023
The Scottish Medicines Consortium Recommends Use of Hansa Biopharma's Idefirix[®] (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients Sep 13
Hansa Biopharma AB and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix in Highly Sensitized Kidney Transplant Patients Aug 23
Second quarter 2022 earnings released: kr3.82 loss per share (vs kr2.98 loss in 2Q 2021) Jul 19 Hansa Biopharma AB (publ) announced that it has received $70 million in funding from NovaQuest Capital Management, L.L.C. Jul 19
Hansa Biopharma Announces First Patient Treated in the Post-Authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients Jul 11
Hansa Biopharma AB (publ) Appoints Peter Nicklin as A New Member of the Board of Director Jul 01
Senior VP recently bought kr346k worth of stock Jun 24
NICE Recommends Use of Hansa Biopharma's Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients Jun 16 Hansa Biopharma AB (publ) Announces Ulf Wiinberg Not to Stand for Re-Election as Director
Hansa Biopharma Completes Enrollment in Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation May 23
Hansa Biopharma Announces Temporary Marketing Authorization in Switzerland for Idefirix (Imlifidase) in Kidney Transplantation May 14
Insider recently bought kr58k worth of stock Apr 29
First quarter 2022 earnings released: kr3.11 loss per share (vs kr2.34 loss in 1Q 2021) Apr 27
Hansa Biopharma Announces U.S. Fda Acceptance of Investigational New Drug (Ind) Application for Phase 3 Study of Imlifidase in Anti-Gbm Disease Apr 20
Full year 2021 earnings released: kr12.33 loss per share (vs kr9.98 loss in FY 2020) Apr 12
Hansa Biopharma AB and Medison Pharma Announces Marketing Authorization in Israel for Idefirix for Desensitization Treatment of Highly Sensitized Kidney Transplant Patients Mar 29
Hansa Biopharma AB Announces Grant of Early Access Post Marketing Authorization for its First-In-Class Treatment Idefirix® (imlifidase) Feb 27
Hansa Biopharma AB Announces Positive Early Access Decision by French Haute Autorité De Santé to Use Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients Feb 26 Shareholder Returns 0RC7 GB Biotechs GB Market 7D -10.6% -0.3% 0.6% 1Y -2.2% -24.5% 4.6%
See full shareholder returns
Return vs Industry: 0RC7 exceeded the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: 0RC7 underperformed the UK Market which returned 4.6% over the past year.
Price Volatility Is 0RC7's price volatile compared to industry and market? 0RC7 volatility 0RC7 Average Weekly Movement 9.3% Biotechs Industry Average Movement 9.5% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.5%
Stable Share Price: 0RC7's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RC7's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.
Show more Hansa Biopharma AB (publ) Fundamentals Summary How do Hansa Biopharma's earnings and revenue compare to its market cap? 0RC7 fundamental statistics Market cap SEK 2.46b Earnings (TTM ) -SEK 654.78m Revenue (TTM ) SEK 189.39m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0RC7 income statement (TTM ) Revenue SEK 189.39m Cost of Revenue SEK 88.19m Gross Profit SEK 101.20m Other Expenses SEK 755.98m Earnings -SEK 654.78m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
Earnings per share (EPS) -9.66 Gross Margin 53.43% Net Profit Margin -345.73% Debt/Equity Ratio -294.7%
How did 0RC7 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/08 19:10 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Hansa Biopharma AB (publ) is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null ABG Sundal Collier Christian Lee ABG Sundal Collier Sponsored Madhu Kumar B. Riley Securities, Inc.
Show 11 more analysts 
